- Zealand Pharma A/S (NASDAQ:ZEAL) has amended its existing financing agreement with Oberland Capital Management LLC, under which Zealand will repurchase $50 million of note principal with a 1.2x prepayment premium.
- Oberland Capital will provide Zealand with up to $75.0 million in incremental capital, of which $50.0 million is to be reserved for M&A and $12.5 million following positive glepaglutide data.
- The updated financial agreement provides a runway extended beyond significant pipeline milestones and into 2023.
- In March, Zealand Pharma announced prioritizing investment in its R&D pipeline programs and streamlining its commercial operations.
- The company said to restructure ops to pursue partnerships for Zegalogue, V-Go, and glepaglutide and dasiglucagon late-stage clinical portfolio.
- Zealand completed patient enrollment in the pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, with full results expected in the third quarter of 2022.
- Price Action: ZEAL shares traded 0.84% higher at $10.83 on the last check Tuesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Zealand Pharma Amends Financing Agreement With Oberland Capital
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks